Search
Skip to Search Results- 2Prado, Carla M.
- 1Baracos, Vickie E.
- 1Bekaii-Saab, Tanios
- 1Cushen, Samantha J.
- 1Daly, Louise
- 1Doyle, L. Austin
-
Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later
Download2016-01-20
Ryan, Aoife M., Power, Derek G., Daly, Louise, Cushen, Samantha J., Ní Bhuachalla, Ēadaoin, Prado, Carla M.
An awareness of the importance of nutritional status in hospital settings began more than 40 years ago. Much has been learned since and has altered care. For the past 40 years several large studies have shown that cancer patients are amongst the most malnourished of all patient groups. Recently,...
-
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
Download2014
Shroff, R., Katz, M. H., Overman, M. J., Khalil, M., Lieffers, J., Varadhachary, G. R., Fogelman, D., Javle, M. , Holmes, H., Prado, C. M.
BackgroundIGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown.MethodsWe evaluated muscle mass at L3 in patients enrolled in a randomized phase...
-
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma
Download2012
Ghosh, Sunita, Doyle, L. Austin, Baracos, Vickie E., Prado, Carla M., Sawyer, Michael B., Bekaii-Saab, Tanios, Shrestha, Suraj
background: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. methods: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib...